Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trialMary O’Brien, Solange Peters, Steven M. Keller et al.|The Lancet Oncology|2022Cited by 738
EANO–ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumoursÉmilie Le Rhun, Matthias Preusser, Matthias Gückenberger et al.|Annals of Oncology|2021Cited by 577
ESMO Guidance for Reporting Oncology real-World evidence (GROW)Luís Castelo-Branco, Miriam Koopman, Anna Pellat et al.|Annals of Oncology|2023Cited by 209
Heterogeneity in cancer guidelines: should we eradicate or tolerate?G. Pentheroudakis, Nikolaos Pavlidis, Rolf A. Stahel et al.|Annals of Oncology|2008Cited by 56
Antibodies to the protein core of the small cell lung cancer workshop antigen cluster-w4 and to the leucocyte workshop antigen CD24 recognize the same short protein sequence leucine-alanine-prolineErich Weber, Rolf A. Stahel, Hans‐Peter Lehmann et al.|Clinical & Experimental Immunology|1993Cited by 36